Skip to main content
TipRanks
Go Ultimate75% OFF

Compare Zealand Pharma (ZLDPF) vs. Competitors

201 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
ZLDPFZealand Pharma$33.65$2.24B5.22-57.67%Moderate BuyUnlock the ZLDPF analyst price target with TipRanks PremiumZLDPFUnlock the ZLDPF top-analyst price target with TipRanks Premium
RDHLRedHill Biopharma$0.35$3.11M-0.36-66.35%―Unlock the RDHL analyst price target with TipRanks PremiumZLDPF vs RDHLUnlock the RDHL top-analyst price target with TipRanks Premium
VSTMVerastem$7.41$933.77M-4.01-19.02%Strong BuyUnlock the VSTM analyst price target with TipRanks PremiumZLDPF vs VSTMUnlock the VSTM top-analyst price target with TipRanks Premium
MNKDMannKind$4.07$1.31B-17.13-18.27%Strong BuyUnlock the MNKD analyst price target with TipRanks PremiumZLDPF vs MNKDUnlock the MNKD top-analyst price target with TipRanks Premium
OTLKOutlook Therapeutics$0.36$87.79M-0.33-79.66%Moderate BuyUnlock the OTLK analyst price target with TipRanks PremiumZLDPF vs OTLKUnlock the OTLK top-analyst price target with TipRanks Premium
BMYBristol-Myers Squibb$61.35$125.40B13.4631.06%Moderate BuyUnlock the BMY analyst price target with TipRanks PremiumZLDPF vs BMYUnlock the BMY top-analyst price target with TipRanks Premium
PFEPfizer$28.47$162.27B40.2413.52%HoldUnlock the PFE analyst price target with TipRanks PremiumZLDPF vs PFEUnlock the PFE top-analyst price target with TipRanks Premium

Performance Comparison

-100%-75%-50%-25%0%25%50%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
ZLDPFZealand Pharma33.65-44.99-57.21%
RDHLRedHill Biopharma0.35-0.71-66.98%
VSTMVerastem7.41-1.86-20.06%
MNKDMannKind4.07-0.99-19.57%
OTLKOutlook Therapeutics0.36-1.55-81.15%
BMYBristol-Myers Squibb61.3516.3036.17%
PFEPfizer28.474.6219.36%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts